Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Annovis Bio (NYSE:ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference.

The presentation is scheduled for September 10, 2025, from 12:00-12:30 pm EDT at the Lotte New York Palace Hotel. The company, which develops therapies for Alzheimer's and Parkinson's disease, offers one-on-one meeting opportunities with Dr. Maccecchini through the conference portal.

News Market Reaction

+0.87%

1 alert

+0.87% News Effect

On the day this news was published, ANVS gained 0.87%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference happening September 8-10, 2025 in Lotte New York Palace Hotel, New York City.

Presentation details

• Date: September 10, 2025
• Time: 12:00-12:30 pm EDT
• Location: Kennedy II, 4^th Floor
• Webcast link

To schedule a one-on-one meeting with Dr. Maccecchini, please use the conference portal or contact meetings@hcwco.com.

For more information, please visit conference website.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

When and where is Annovis Bio (ANVS) presenting at the H.C. Wainwright Conference?

Annovis Bio is presenting on September 10, 2025, from 12:00-12:30 pm EDT at the Kennedy II, 4th Floor of the Lotte New York Palace Hotel in New York City.

How can investors schedule meetings with Annovis Bio's CEO at the H.C. Wainwright Conference?

Investors can schedule one-on-one meetings with CEO Dr. Maria Maccecchini through the conference portal or by contacting meetings@hcwco.com.

What types of diseases does Annovis Bio (ANVS) focus on?

Annovis Bio focuses on developing transformative therapies for neurodegenerative diseases, specifically Alzheimer's disease (AD) and Parkinson's disease (PD).

Who is presenting on behalf of Annovis Bio at the H.C. Wainwright Conference?

Dr. Maria Maccecchini, the CEO of Annovis Bio, will be presenting at the conference.